There's been a sharp increase in unsubtyped influenza A detected in Canada and beyond over the last few weeks.
Compared to the previous two seasons, influenza only passed the epidemic threshold (5% test positivity) in January compared to a October/November start.
What's up? 🧵
By definition, influenza A without a subtype remains unidentified.
However, given that influenza A shares a gene with H5N1, it is still possible that at least some of those positive results are in fact H5N1.
On the other hand, H5N1 numbers in wastewater are not universally increasing. Non-rural locations such as Oceanside and Southeast San Francisco show a decrease, for example.
I'll have to dig more into waste water stats later.
My impression is that there are multiple factors involved. On one hand we have immune dysregulation from previous COVID infections, opening the door to more severe seasonal influenza.
Additionally, we also see H5N1 in a limited subset of human cases.
It is tough to point to a singular cause in this year's influenza A spike, but things are made even more challenging by a reporting blackout from the CDC.
You'll need to rely on state and local health authorities for surveillance data, and GISAID for sequencing.
One thing is clear: airborne precautions should continue be taken. If you're COVID-informed, you already know this.
Make sure you adjust your nose wires in a way that improves your fit. Avoid loose-fitting KN95s or KF95s in favor of N95, elasto, PAPR.
Correcting myself, H5N1 is a subtype of influenza A. What I meant to say is that there's a shared gene between seasonal influenza A viruses and H5N1—the M1 and M2 matrix genes.
Amid the gloom and doom, I'm excited to share news that gives me hope.
Invivyd has announced positive initial findings from an ongoing clinical trial of a monoclonal antibody to be used as a pre-exposure prophylactic to prevent COVID-19 infections.
Here are the highlights: 🧵
Invivyd has been developing a monoclonal antibody to prevent COVID infection.
The idea is you'd get it once or twice a year and get better protection against COVID than available vaccines.
This could make it much easier to avoid long COVID, especially combined with respirators.
VYD2311 is a monoclonal antibody with neutralization ability against various lineages including XBB.1.5, and it reportedly achieves increased neutralization over pemivibart (pemgarda).
Note: JN.1 neutralization has been confirmed in vitro for pemivibart.